Array Biopharma Wins Two Important Deals In Six Months, But Wall Street Shrugs
This article was originally published in The Pink Sheet Daily
Executive Summary
To management's frustration, the biotech's deals with Novartis and Amgen haven't helped its market cap, one more sign that validating deals with Big Pharma don't move investors.
You may also be interested in...
Array Expects To Have Phase III MEK Inhibitor All To Itself, Without Partner Novartis
Following Novartis’ oncology deal with GSK, which included another MEK inhibitor, Array anticipates getting the asset back for itself. Novartis would be obliged to continue supporting Phase III studies, Array says, as part of a pipeline update in second-quarter earnings call.
Over A Decade In The Making, MEK Inhibitors Break Through In Melanoma
As if moving on from failures of the past, MEK inhibitors are now being positioned as part of the next standard of care in BRAF-mutant melanoma. Glaxo prepares to file trametinib as a monotherapy in 2012, after reporting striking Phase III results, while Novartis/Array’s MEK 162 demonstrates value in area of unmet need.
Array Strikes New Deal For Cancer Drug With Longtime Partner Genentech, Taking $28M Upfront
Genentech gains a second compound that regulates cell cycle progression and Array receives cash to advance four in-house drugs through the clinic.